Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Professor Aurélien Marabelle joins the Board of Directors of the Society for Immunotherapy of Cancer (SITC)
Professor Aurélien Marabelle, physician-scientist at Gustave Roussy, has been elected to a three-year term on the Board of Directors of the SITC, the leading international scientific society dedicated to cancer immunotherapy. His term will begin in January 2026, during the annual renewal of one-third of the board members.
Published on
Professor Aurélien Marabelle, physician-scientist at Gustave Roussy, has been elected to a three-year term on the Board of Directors of the SITC, the leading international scientific society dedicated to cancer immunotherapy. His term will begin in January 2026, during the annual renewal of one-third of the board members.
Founded in 1985, the SITC is celebrating its 40th anniversary and brings together more than 2,400 experts from 42 countries. This election highlights Professor Marabelle’s pioneering role and Gustave Roussy’s commitment to therapeutic innovation. He will be the first and only French and European representative on the SITC Board.
Trained at the École Normale Supérieure de Lyon, King’s College London, and Stanford University, Professor Marabelle works at the intersection of clinical and translational research. He is an oncologist in the Department of Therapeutic Innovation and Early Trials (DITEP), Professor of Clinical Immunology at Université Paris-Saclay, and leads the INSERM Translational Research Laboratory in Immunotherapy (LRTI) at Gustave Roussy. He also coordinates the RHU (Hospital-University Research) program REMISSION, a project supported by the France 2030 plan to accelerate access to immunotherapy.
A specialist in next-generation immunotherapies, he is the author of more than 250 scientific publications and leads numerous early-phase clinical trials. He co-founded the French Society for Cancer Immunotherapy (FITC), where he currently serves as Vice-President, and sits on several international scientific committees.
“It is an honor to join the SITC Board of Directors at a strategic moment of exponential growth in immunotherapy approaches. This election commits me to promoting an ambitious scientific vision based on European academic excellence, while also fostering international collaboration, broad dissemination of knowledge, and equitable access to innovation,” he stated.
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
